Ardelyx (ARDX) Income from Continuing Operations (2013 - 2026)
Ardelyx (ARDX) posted Income from Continuing Operations of 37605000.0 for Q1 2026, down 9139.56% on a QoQ basis from 407000.0 in Q4 2025, and up 8.6% year-over-year from 34626594.45 in Q1 2025.
Ardelyx (ARDX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ardelyx's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 37605000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 8.6% year-over-year to 37605000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58060000.0 (down 7.99% YoY) and the FY2025 annual result came in at 61599000.0, down 57.4% from the prior year.
- Income from Continuing Operations was 37605000.0 for Q1 2026 at Ardelyx, down from 407000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10695000.0 in Q4 2022 and bottomed at 41144000.0 in Q1 2025.
- A 5-year average of 15977294.12 and a median of 19079000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 129.52% — and 2023, when it slumped 369.3%.
- Ardelyx's Income from Continuing Operations stood at 10695000.0 in 2022, then tumbled by 369.3% to 28802000.0 in 2023, then surged by 116.13% to 4645000.0 in 2024, then plunged by 108.76% to 407000.0 in 2025, then plunged by 9139.56% to 37605000.0 in 2026.
- Business Quant data shows ARDX's Income from Continuing Operations at 37605000.0 in Q1 2026, 407000.0 in Q4 2025, and 969000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | -37.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.61 Mn |
| Dec 31, 2025 | -407,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -41.14 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | -16.45 Mn |
| Mar 31, 2024 | -26.52 Mn |
| Dec 31, 2023 | -28.80 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -26.77 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -26.94 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -36.23 Mn |
| Sep 30, 2021 | -43.59 Mn |
| Jun 30, 2021 | -45.19 Mn |